Diabetic foot ulcers are open wounds, usually on the feet, that develop in people with diabetes because of nerve damage, poor blood circulation and delayed wound healing. They are among the most burdensome chronic complications of diabetes, often requiring prolonged wound care and infection control. The CSIR-IICT formulation moved through the full preclinical chain before the transfer: botanical standardisation of the plant material, pharmacological and mechanism-of-action studies, analytical and pharmacokinetic evaluation, formulation development, GMP process development, stability testing, and safety studies compliant with Good Laboratory Practice. Completing this chain is what produces an IND-ready data package - the dossier a sponsor needs before regulators will permit the first trials in humans. Viridis Biopharma will now handle regulatory submissions to the CDSCO and the US Food and Drug Administration and take the candidate into clinical evaluation.

India has an unusually large medicinal-plant tradition but a thin record of converting it into medicines that clear modern regulatory scrutiny. The phytopharmaceutical category exists precisely to bridge that gap: it lets a plant-derived product be approved on evidence of quality, safety and efficacy rather than on traditional use alone. A publicly funded CSIR laboratory carrying a candidate to IND-ready status and then licensing it to industry is the intended model of the CSIR Phytopharmaceutical Mission - public money absorbs the risky early science, private capital funds the expensive clinical stage. The target condition also matters: with roughly 101 million people living with diabetes in India, foot ulcers are a large and under-served clinical burden, and an affordable indigenous therapy would have a direct public health effect.